{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:42:46Z","timestamp":1777588966906,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Endourology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To prospectively assess early post-transurethral prostate surgery (TUPS) urinalysis changes and bacteriuria with its clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with benign prostate obstruction enrolled for TUPS were prospectively assessed. Patients were assessed at 2, 4, 8, 12, and 24 weeks postoperatively by the dysuria-visual-analogue-scale (DVAS), international prostate symptom scores (IPSS)-quality of life, uroflow, and postvoid residual. Routine urinalysis was performed before discharge and at all visits. Midstream urine culture (MSUC) was performed before discharge, and 4 and 12 weeks postoperatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At final analysis, 152 patients were evaluable. Significant pyuria was reported in 52%, 96.1%, 94.1%, 71.7%, 78.9%, and 52.5% in, before discharge, 2-, 4-, 8-, 12-, and 24-week urinalysis postoperative, respectively. The mean time to nonsignificant pyuria (95% confidence interval [CI]) was 19.1 (17.5\u201320.7), 20.1 (17.3\u201322.9), 15.8 (12.8\u201318.8), and 14 (10.3\u201317.8) weeks after prostate resection, vaporization, enucleation, and incision, respectively (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.03). Regardless the TUPS technique, half of patients had significant pyuria at 24 weeks postoperative. MSUC was positive in 37\/152 (24.3%), 3\/152 (2%), 23\/152 (15.1%), and 5\/152 (3.3%) preoperatively, before discharge, and 4 and 12 weeks postoperative, respectively. Only positive preoperative urine leukocyte esterase independently predicted positive 4-week MSUC (odds ratio 3.8, 95% CI 1.3\u201311.1,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.013). No significant correlation was found between IPSS or DVAS and positive MSUC, nor between IPSS and postoperative pyuria at different follow-up points (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&gt;\u20090.05). However, the degree of postoperative dysuria was significantly correlated with postoperative pyuria count by urinalysis at 2 weeks (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.69,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.03), 8 weeks (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.26,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001), and 12 weeks (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.23,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>There is a persistent but gradually declining pyuria and microhematuria following TUPS up to 6 months postoperative. An earlier resolution was noted following prostate incision and enucleation. While routine urine analysis screening in these months would be of no clear clinical value, a routine urine culture would be of a reasonable significance at 1 month postoperatively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/end.2023.0667","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T13:17:54Z","timestamp":1713014274000},"page":"629-636","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Headache of Post-Transurethral Prostate Surgery Pyuria: Pursuit for Evidence"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-0161","authenticated-orcid":false,"given":"Ahmed M.","family":"Elshal","sequence":"first","affiliation":[{"name":"Depatment of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled A.","family":"Allam","sequence":"additional","affiliation":[{"name":"Depatment of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed E.","family":"Abolazm","sequence":"additional","affiliation":[{"name":"Depatment of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Nabeeh","sequence":"additional","affiliation":[{"name":"Depatment of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Osman","sequence":"additional","affiliation":[{"name":"Depatment of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mou.0000193368.91823.1b"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000019617"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000052452"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/506398"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.08.013"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08907.x"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.109993"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000048427"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000050305.05345.40"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.042"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.078"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1410052"},{"key":"e_1_3_6_14_2","unstructured":"McVary KT Roehrborn CG Avins Al et al. American Urological Association Guidelines; Managment of BPH 2010. Available from: http:\/\/www.auanet.org\/content\/guidelines-and-quality-care\/clinical-guidelines.cfm?sub=bph [Last accessed: January1 2018]."},{"key":"e_1_3_6_15_2","unstructured":"Gravas TB Bachmann A Drake M et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS) incl. benign prostatic obstruction (BPO): European association of Urology. 2015. Available from: https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-Non-Neurogenic-Male-LUTS-Guidelines-2015-v2.pdf [Last accessed: July28 2018]."},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuro.2013.02.014"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2019.117"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7262.2006.00188.x"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.11.018"},{"issue":"2","key":"e_1_3_6_20_2","first-page":"571","article-title":"Prophylactic antibiotic use in transurethral prostatic resection: A meta-analysis","volume":"167","author":"Berry A","year":"2002","unstructured":"Berry A, , Barratt A. Prophylactic antibiotic use in transurethral prostatic resection: A meta-analysis. J Urol, 2002; 167(2 Pt 1):571\u2013577.","journal-title":"J Urol"}],"container-title":["Journal of Endourology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/end.2023.0667","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/end.2023.0667","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/end.2023.0667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:15:59Z","timestamp":1777407359000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/end.2023.0667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1089\/end.2023.0667"],"URL":"https:\/\/doi.org\/10.1089\/end.2023.0667","relation":{},"ISSN":["0892-7790","1557-900X"],"issn-type":[{"value":"0892-7790","type":"print"},{"value":"1557-900X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}